Mankind Pharma’s Q3 FY25 net profit declined 16% YoY to ₹385 crore despite a 24% revenue increase to ₹3,230 crore. Domestic revenues rose 17%, exports more than doubled, and consumer health grew 30%.
Sebi relaxes F&O monitoring norms for intraday limits, removes penalty for breach
Sebi has mandated exchanges to monitor at least four intraday position limits for index derivatives starting April 1, 2025. While breaches won’t incur penalties yet,